Abstracts

713 – Salivary miR-324-5p as a Novel Biomarker of Periodontal Status Among People With HIV Undergoing ART

Background Periodontitis is a prevalent inflammatory disease of tooth-supporting tissues, causing systemic diseases. microRNA (miRNA) expression in extracellular vesicles (EVs) can reflect periodontal status. However, the specific miRNAs associated with periodontal status in people with HIV (PWH) remain unclear. This cross-sectional study aimed to investigate the salivary miRNAs in EVs among PWH with periodontitis undergoing…

222 – Lymphoid Organ-Chip as a Model to Study HIV Immunopathogenesis and Reservoir

Background A psychologically relevant human system is required to better understand HIV immunopathogenesis and reservoir in secondary lymphoid organs. Recent studies demonstrate that lymphoid organ-chip, a microfluidic system with high-density human PBMC cultured in 3D collagen matrix, can recapitulate key features of human lymphoid tissues. Therefore, we hypothesize that lymphoid organ-chip may serve as a…

223 – Elevated Kynurenine/Tryptophan in Suppressed PWH: Potential Cause of Residual Immune Dysfunction?

Background People with HIV (PWH), even those who start ART early and restore CD4 counts, remain at higher risk for TB and cancer. HIV induces IDO, an enzyme in the immunomodulatory kynurenine pathway (KP), which leads to increases in kynurenine/tryptophan (K/T) ratios and related metabolites. Whether KP effects underlie the persistent immunosuppression in treated PWH…

238 – Single-Cell Profiling of HIV-1 Infection and Response to Early ART in an Ex Vivo Human Tonsil Model

Background HIV-1 pathogenesis is driven by rapid depletion and infection of CD4⁺ helper T cells in lymphoid tissues during acute infection. The mechanisms underlying early CD4⁺ loss and the capacity of early antiretroviral therapy (ART) to preserve immune homeostasis and reverse pathology in these compartments remain incompletely defined. We hypothesized that acute HIV-1 infection with…

781 – Dolutegravir+Lamivudine vs Efavirenz Regimen in Adults With HIV-Tuberculosis: A Randomized Trial

Background To evaluate the efficacy and safety of double-dose dolutegravir plus lamivudine (2DR) versus an efavirenz-based three-drug regimen (3DR) in antiretroviral-naïve adults coinfected with HIV and tuberculosis (TB) who had initiated rifampicin-based anti-TB therapy within the previous two weeks.  Methods In this multicenter, open-label, randomized trial (ChiCTR2300075493), participants were assigned (1:1) to receive either dolutegravir…

1000 – Five-Year German PrEP Cohort Reveals High HIV Protection and Persistent STI Burden

Background To evaluate adherence patterns, effectiveness, and sexually transmitted infection (STI) incidence among pre-exposure prophylaxis (PrEP) users in Germany and identify strategies to optimize HIV and STI prevention through individualized care and alternative PrEP modalities. Methods A single-site, pseudonymized prospective cohort study was conducted in Hamburg, Germany from December 2019 to September 2024. Clinical and…

279 – Sex Differences in Immunologic Response to Letermovir-Mediated CMV Suppression in People With HIV

Background In ART-suppressed people with HIV (PWH), asymptomatic CMV suppression with letermovir reduced several inflammatory proteins causally linked to cardiovascular disease and cancer. However, an early transient increase in inflammation was observed, potentially due to suppression of CMV’s immunoregulatory viral IL-10 (vIL-10). Since women have less STAT3 signaling after IL-10 receptor (IL-10R) stimulation than men,…

562 – Evaluation of HIV-1 Dolutegravir Resistance Patterns and Associated Clinical Factors in Cameroon

Background In low- and middle-income countries (LMICs), varying rates of emerging resistance to integrase inhibitors (INI) have been reported, but knowledge on INI mutational patterns and associated clinical factors remains limited. We herein evaluated INI-resistance and associated clinical factors among people with HIV (PWH) who failed dolutegravir (DTG)-based antiretroviral therapy (ART) in Cameroon, a country…

892 – HIV Attributable Fraction of US COVID-19 Hospitalizations by Race/Ethnicity, 2020-2022

Background People living with HIV (PLWH) are at increased risk of severe COVID-19 outcomes, including hospitalizations, relative to people living without HIV. Additionally, racialized and geographic disparities in social determinants of health and access to care impact both HIV and COVID-19 outcomes. We investigated the fraction of COVID-19 hospitalizations attributable to HIV and lack of…